Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?
Last Updated: Friday, July 17, 2026
This review article discusses the safety and effectiveness of CD19-directed CAR T-cell therapy lisocabtagene maraleucel in the treatment of relapsed or refractory DLBCL, including data from the Transcend NHL 001 trial.
